• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Dilip: when are you going to fire the US CEO ?

Quote

anonymous

Guest
I struggle to believe you’re foolish enough to let this mess continue.

But maybe I’m wrong, and you are that blind to not just the losses in the US, but that the reputation of Sun has been deeply affected.
Doctors don’t want to Rx Sun due to historical pricing, poor quality/recalled products and employees who loathe what’s been going on.
Here’s a thought that no one ever speaks of in regards to the Ilumya FAILURE:

Beyond all the screw ups associated with the launch, what if a key underlying issue
with uptake among derms is their putting the screws to Sun for being price-abused for so many years.

Dilip: you were only concerned about derms being able to hurt Ilumya, well guess what little fella ?

Now they are effing YOU. So who is laughing now?

Signed,

“The Reluctant Dermatologist”
 




























anonymous said:
Sorry we let you go, but lazy Americans are a cancer to us.
We must hire more Asian and brown recruits who bring us strength and diversity.

Signed,
Dilip
Click to expand...
There is some truth to this.
This is how they feel about us.
That is why I am leaving the company for an AMERICAN owned company.
That doesn't mean they only hire white men. They hire a diverse group of people that were born in AMERICA. If you commit what is considered a felony in this country, you get terminated.
 




anonymous said:
I struggle to believe you’re foolish enough to let this mess continue.

But maybe I’m wrong, and you are that blind to not just the losses in the US, but that the reputation of Sun has been deeply affected.
Doctors don’t want to Rx Sun due to historical pricing, poor quality/recalled products and employees who loathe what’s been going on.
Here’s a thought that no one ever speaks of in regards to the Ilumya FAILURE:

Beyond all the screw ups associated with the launch, what if a key underlying issue
with uptake among derms is their putting the screws to Sun for being price-abused for so many years.

Dilip: you were only concerned about derms being able to hurt Ilumya, well guess what little fella ?

Now they are effing YOU. So who is laughing now?

Signed,

“The Reluctant Dermatologist”
Click to expand...

Hopefully 2020 brings us new leadership.
 




anonymous said:
I struggle to believe you’re foolish enough to let this mess continue.

But maybe I’m wrong, and you are that blind to not just the losses in the US, but that the reputation of Sun has been deeply affected.
Doctors don’t want to Rx Sun due to historical pricing, poor quality/recalled products and employees who loathe what’s been going on.
Here’s a thought that no one ever speaks of in regards to the Ilumya FAILURE:

Beyond all the screw ups associated with the launch, what if a key underlying issue
with uptake among derms is their putting the screws to Sun for being price-abused for so many years.

Dilip: you were only concerned about derms being able to hurt Ilumya, well guess what little fella ?

Now they are effing YOU. So who is laughing now?

Signed,

“The Reluctant Dermatologist”
Click to expand...

How are book sakes going Mr. Reluctant Billionaire ?
I’ve got a bunch of derms that are just so pissed at Sun. My colleagues talk trash in accounts, it just sucks here.
 




anonymous said:
I struggle to believe you’re foolish enough to let this mess continue.

But maybe I’m wrong, and you are that blind to not just the losses in the US, but that the reputation of Sun has been deeply affected.
Doctors don’t want to Rx Sun due to historical pricing, poor quality/recalled products and employees who loathe what’s been going on.
Here’s a thought that no one ever speaks of in regards to the Ilumya FAILURE:

Beyond all the screw ups associated with the launch, what if a key underlying issue
with uptake among derms is their putting the screws to Sun for being price-abused for so many years.

Dilip: you were only concerned about derms being able to hurt Ilumya, well guess what little fella ?

Now they are effing YOU. So who is laughing now?

Signed,

“The Reluctant Dermatologist”
Click to expand...

This has played out just as predicted. Poor strategy along with terrible execution along with derms that have a longstanding issue with Sun’s abusing them are now flexing their power choice. This is the subtle elephant in the room that no one talks about.

Dilip has invested hundreds and hundreds of millions in the US and he’s getting his ass handed to him.
 








anonymous said:
This has played out just as predicted. Poor strategy along with terrible execution along with derms that have a longstanding issue with Sun’s abusing them are now flexing their power choice. This is the subtle elephant in the room that no one talks about.

Dilip has invested hundreds and hundreds of millions in the US and he’s getting his ass handed to him.
Click to expand...

Dilip will return to the states to take the docs out on dinner dates.
 




anonymous said:
Hopefully 2020 brings us new leadership.
Click to expand...

Unfortunately the next change involves a massive layoff. So if you are crying for change you should pack your bags a get out now. It is coming. Not one of the brands is producing to expectations. A few are pushing but not up to being self sufficient yet. You don’t get to be a billionaire by giving your money away in bad deals. US brands are a bad deal. Look for selling off dermatology branded in the next 18 months. This goes with support staff, so get a good sturdy box for your stuff.

Levulan sales are about over between the ordering system and increased competition. Ilumya sales will decline massively and not grow at all as Janssen is aggressively pursuing Buy & Bill with their older biologic. Absorica will be an auto-switch out soon and coverage will be filled by exception only. Oncology sales are weak and under forecast. Does any of this sound appealing if you managed this? So you see, replacing the AG has never been in the table. Wether to eliminate you or not is the only consideration being discussed at very high levels. Even then it is not so much if but when.
 




anonymous said:
Unfortunately the next change involves a massive layoff. So if you are crying for change you should pack your bags a get out now. It is coming. Not one of the brands is producing to expectations. A few are pushing but not up to being self sufficient yet. You don’t get to be a billionaire by giving your money away in bad deals. US brands are a bad deal. Look for selling off dermatology branded in the next 18 months. This goes with support staff, so get a good sturdy box for your stuff.

Levulan sales are about over between the ordering system and increased competition. Ilumya sales will decline massively and not grow at all as Janssen is aggressively pursuing Buy & Bill with their older biologic. Absorica will be an auto-switch out soon and coverage will be filled by exception only. Oncology sales are weak and under forecast. Does any of this sound appealing if you managed this? So you see, replacing the AG has never been in the table. Wether to eliminate you or not is the only consideration being discussed at very high levels. Even then it is not so much if but when.
Click to expand...

Interesting assessment.
Perhaps the biggest reason that you may be right is that Abhay is still here.
In any other organization, he would have been long fired. So that gives credence to the shutter-the-doors theory.
“We sent our soldier to the US, he failed. Therefore we’ll fold up the tent and close shop.”
Not out of the question at all.
 




anonymous said:
Unfortunately the next change involves a massive layoff. So if you are crying for change you should pack your bags a get out now. It is coming. Not one of the brands is producing to expectations. A few are pushing but not up to being self sufficient yet. You don’t get to be a billionaire by giving your money away in bad deals. US brands are a bad deal. Look for selling off dermatology branded in the next 18 months. This goes with support staff, so get a good sturdy box for your stuff.

Levulan sales are about over between the ordering system and increased competition. Ilumya sales will decline massively and not grow at all as Janssen is aggressively pursuing Buy & Bill with their older biologic. Absorica will be an auto-switch out soon and coverage will be filled by exception only. Oncology sales are weak and under forecast. Does any of this sound appealing if you managed this? So you see, replacing the AG has never been in the table. Wether to eliminate you or not is the only consideration being discussed at very high levels. Even then it is not so much if but when.
Click to expand...

well, we know we can’t keep going like it’s been going. Sumthin’ has to give.
 




anonymous said:
This has played out just as predicted. Poor strategy along with terrible execution along with derms that have a longstanding issue with Sun’s abusing them are now flexing their power choice. This is the subtle elephant in the room that no one talks about.

Dilip has invested hundreds and hundreds of millions in the US and he’s getting his ass handed to him.
Click to expand...

The Reluctant Billionaire being devalued by the US market.
 




It is important to remember that only the “branded Derm “ will go away. It clearly was not as lucrative as they originally considered and the amount of competition exceeded their competitive threshold.
 




anonymous said:
It is important to remember that only the “branded Derm “ will go away. It clearly was not as lucrative as they originally considered and the amount of competition exceeded their competitive threshold.
Click to expand...
You think Ilumya will survive ? Absorica is suffering big time and Biofrontera is poised to make a real run on our Levulan business. I think all of Derm products is up for grabs.
 








Top Bottom
Back
Quote